News | FFR Technologies | July 09, 2020

Acist Launches New Advance in FFR Microcatheters

The Acist Navvus II Rapid Exchange FFR MicroCatheter delivers even more flexibility and a streamlined crossing profile to assess complicated lesions

The Acist Navvus II Rapid Exchange FFR MicroCatheter delivers even more flexibility and a streamlined crossing profile to assess complicated lesions.

The Acist Navvus II Rapid Exchange FFR MicroCatheter delivers even more flexibility and a streamlined crossing profile to assess complicated lesions.


July 9, 2020 – Acist Medical Systems Inc., a Bracco Group Company, announced the global launch of its Acist Navvus II Rapid Exchange fractional flow reserve (FFR) microcatheter, the second-generation microcatheter for use with its Acist RXi Rapid Exchange FFR System.

FFR measurements provide assessment of arterial lesion severity and inform intervention strategy in both diagnosis and treatment of coronary artery disease. This latest advance delivers the same level of control, consistency and accuracy that physicians have come to expect from the original Navvus microcatheter, with valuable new enhancements. Specifically, the Acist Navvus II features a streamlined crossing contour, 28 percent more flexibility[1] and a lesion entry profile reduced by 15 percent.[2] The result is a highly deliverable microcatheter that may improve procedural efficiency.

The Navvus II Rapid Exchange MicroCatheter and its predecessor, Navvus, are the only coronary physiology products that allow the use of the physician’s 0.014 inch guidewire of choice. This market distinction may enable more efficient, faster diagnostic and post-PCI physiological assessment because wire position is maintained throughout the procedure.

Recently, the FFR-SEARCH study reported an average of 5 minutes per lesion to assess physiology following the intervention using the Acist microcatheter-based system.[3] FFR-SEARCH is a robust and independent, physician-sponsored study that utilized a prospective, all-comers registry and over 600 patients were analyzed.

“This latest advance represents the company’s continued strategic commitment to our market-defining FFR technology,” said Kristen Knox, SVP, general manager, Acist Medical Systems. “Physicians know they can rely on Navvus—and now Navvus II—to easily and quickly guide treatment decisions by invasive physiologic measurement.”

For more information https://acist.com/products/acist-rxi/navvusii-catheter/

 
References:

1. TR-07888: Compared with Navvus FFR MicroCatheter in benchtop testing. Data on file at ACIST. May not be indicative of clinical performance.

2. TR-08707: Compared with Navvus FFR MicroCatheter in benchtop testing. Data on file at ACIST. May not be indicative of clinical performance.

3. Rutger J. van Bommel, Kaneshka Masdjedi, Roberto Diletti, et al. Routine Fractional Flow Reserve Measurement After Percutaneous Coronary Intervention. The FFR-SEARCH Study. Circulation: Cardiovascular Interventions. 2019;12. Originally published 25 Apr 2019. https://doi.org/10.1161/CIRCINTERVENTIONS.118.007428. 2019;12

 


Related Content

News | Cath Lab

May 13, 2026 — According to a recently released report, the global cath lab services market was valued at $46.0 billion ...

Home May 13, 2026
Home
News | Cath Lab

April 16, 2026 — A national study led by investigators from Cedars-Sinai Health Sciences University found that ...

Home April 20, 2026
Home
News | Cath Lab

April 6, 2026 —Stereotaxis has received U.S. Food and Drug Administration 510(k) clearance for its Synchrony system ...

Home April 07, 2026
Home
News | Cath Lab

March 31, 2026 — Solo Pace Inc. has announced the commercial release of the SoloPace Fusion Temporary Pacing System. The ...

Home April 03, 2026
Home
News | Cath Lab

March 25, 2026 — Royal Philips has launched its intuitive interventional guidance platform, IntraSight Plus, which is ...

Home March 26, 2026
Home
Feature | Cath Lab | Kyle Hardner

Since receiving FDA approval in 2016, intravascular lithotripsy (IVL) systems have grown in popularity among ...

Home November 14, 2025
Home
News | Cath Lab

Nov. 11, 2025 — FastWave Medical has successfully completed enrollment in its 30-patient coronary feasibility study and ...

Home November 13, 2025
Home
News | Cath Lab

Oct. 28, 2025 — Results from the first-of-its-kind randomized PROCTOR trial found that a strategy of saphenous vein ...

Home November 04, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Results from the PREVUE-VALVE study suggest that there are currently at least 4.7 million people aged 65 ...

Home October 29, 2025
Home
News | Cath Lab

Oct. 25, 2025 — Medtronic plc has announced the launch of the Stedi Extra Support guidewire, designed to enhance ...

Home October 28, 2025
Home
Subscribe Now